Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Publication|Articles|July 1, 2025
Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
Targeted Therapies and Genomic Testing Take Center Stage at ASCO 2025
Author(s)Mike Hennessy Jr, Chairman and CEO
Advertisement
Advertisement
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, a wave of practice-changing data were presented across solid tumors and hematologic malignancies, reinforcing the growing role of personalized medicine and novel immunotherapies in shaping pharmacy practice.
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement